Cantor Fitzgerald Maintains Overweight on AbbVie, Lowers Price Target to $240

Benzinga Newsdesk www.benzinga.com Negative 83.9%

Neg 83.9% Neu 0% Pos 0%

Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and lowers the price target from $250 to $240.